Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2025 / July / Allen C. Ho Power List Perspectives
Retina Insights Opinions

Allen C. Ho Power List Perspectives

Our 2025 Power Lister winners take a look at current trends in their subspecialties

By Julian Upton 7/25/2025 3 min read

Share

Allen C. Ho

A quick Q&A on the future of the retina spac with Allen C. Ho, Wills Eye Hospital Director of Retina Research and Co-Director of Retina Service; Professor of Ophthalmology, Thomas Jefferson University, Philadelphia, PA.

What is the most exciting thing happening in retina right now?

Multiple shots on goal based on new translational science to address unmet need. I am excited by the extensive translational science and resource investments in improving our strategies for important common retinal diseases such as diabetic retinopathy and age-related macular degeneration (AMD) as well as new approaches to arguably our most neglected patients with great visual disabilities, for example, the broad array of inherited retinal degenerations. The retina innovation ecosystem is robust!

Can you make a bold prediction for the future of retina treatment?

In human gene therapy was first approved in 2017 and began in the subretinal space (Spark's Luxturna [voretigene] pioneered by Jean Bennett and Albert Maguire for Leber Congenital Amaurosis RPE65 biallelic mutation) and since then over 30 gene therapies have been approved across many fields of medicine. In the next five years, we will bring it back to the eye and see more gene therapies approved for retinal diseases.

About the Author(s)

Julian Upton

Julian Upton is Group Editor of The Ophthalmologist and The New Optometrist. With 20+ years' experience of the magazine industry, he has covered many facets of science and healthcare.

More Articles by Julian Upton

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: